PHYTATE (IP-6) may have therapeutic p... - Osteoarthritis Ac...

Osteoarthritis Action

1,822 members523 posts

PHYTATE (IP-6) may have therapeutic potential in BCP crystal-associated musculoskeletal syndromes. [Might reduce bone spurs?]

ElliotGreen profile image
1 Reply

This is speculative, but I want to make a note of it.

I'm researching IP-6 (also called phytate, phytic acid, or Inositol hexaphosphate). I’m interested in it for a number of reasons, including its benefits for Parkinson’s disease (which I have) and as an anti-cancer therapy.

What about osteoarthritis?

There is some indication that it may reduce pathological calcifications in some instances. Given that I have problems with bone spurs in my foot, this seems significant to me.

Check out this article:

Rosenthal, Ann K. "Basic calcium phosphate crystal-associated musculoskeletal syndromes: an update." Current opinion in rheumatology 30.2 (2018): 168.

ncbi.nlm.nih.gov/pmc/articl...

Basic calcium phosphate (BCP) crystals are associated with two important musculoskeletal syndromes. Deposition of BCP crystals in tendons, bursae, and other soft tissues around joints causes calcific periarthritis, whereas intra-articular BCP crystals contribute to osteoarthritis and cause the highly destructive arthritis known as Milwaukee Shoulder Syndrome. The epidemiology and natural history of these syndromes are poorly understood, and because the pathogenesis remains unclear, few targeted therapies are available.”

[...]

“There are few effective treatment strategies for BCP crystal-associated arthritis and dietary risk factors are not well defined. Joubert et al. recently proposed that phytate (myo-inositol hexaphosphate) might contribute to pathologic vascular calcification in renal disease patients. Phytate is a polyphosphate found in nuts, whole grains, and seeds and is a natural inhibitor of calcification in a class with matrix Gla protein, PPi, and fetuin. Patients with renal disease are often on low phytate diets and levels are further reduced by dialysis. Phytate supplementation has been shown to decelerate vascular calcification in aging rats. Low levels may correlate with valvular calcification in elderly humans. Sufficient levels would be difficult to achieve with diet alone, but intravenous forms of phytate are in early drug development stages. This interesting work postulates a potential role for dietary factors in pathologic BCP crystal formation and further studies may reveal a therapeutic potential for phytate in BCP crystal-associated musculoskeletal syndromes.

Anyway, this looks little bit interesting, but maybe dietary phytate wouldn’t be enough to make a difference? I also don’t know how significant BCP is in contributing to osteoarthritis. But my interest is piqued.

Any comments? Any other dietary suggestions for reducing bone spurs?

Written by
ElliotGreen profile image
ElliotGreen
To view profiles and participate in discussions please or .
Read more about...
1 Reply
ElliotGreen profile image
ElliotGreen

Bernabei, Ilaria, et al. "Cartilage calcification in osteoarthritis: mechanisms and clinical relevance." Nature Reviews Rheumatology (2022): 1-18.

nature.com/articles/s41584-...

“Inositol phosphates SNF472, the hexasodium salt of myo-inositol hexaphosphate, binds to hydroxyapatite with an affinity of 1–10 μM, preventing crystal nucleation and growth. SNF472 inhibited vascular smooth muscle cell calcification with a half-maximal inhibitory concentration close to 1 μM, whereas it showed no deleterious effects on bone mineralization in dogs or in rat osteoblasts. SNF472, studied in two different rat models of cardiovascular calcification (vitamin D 3 -induced non-uraemic or in adenine-induced uraemic models), inhibited the development and progression of vascular calcification.

“In completed phase II studies, SNF472 administered parenterally for the treatment of calciphylaxis or coronary artery calcifications showed good safety and tolerability, as well as encouraging efficacy 246 . New compounds based on myo-inositol hexaphosphate have been synthesized and developed with superior potency and pharmacokinetics 247 . In particular, one of these derivatives, (OEG 2 ) 2 - IP4, could more potently inhibit vascular smooth muscle cell cal- cification (half-maximal inhibitory concentration ∼0.1 μM) and its subcutaneous route of administration is more convenient compared with SNF472. All these inositol phosphate derivatives have been developed for cardiovascular and renal calcification disorders; their effectiveness in joint calcification and OA remains to be evaluated.